L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study

被引：0
|
作者：
Duell, J. [1 ]
Gonzalez Barca, E. [2 ]
Liberati, A. M. [3 ]
Salles, G. [4 ]
Gaidano, G. [5 ]
Jurczak, W. [6 ]
Nagy, Z. [7 ]
Papajlk, T. [8 ,9 ]
Andre, M. [10 ]
Zinzani, P. L. [11 ]
Kalakonda, N. [12 ]
Ambarkhane, S. [13 ]
Weirather, J. [13 ]
Maddocks, K. [14 ]
Dreyling, M. [15 ]
机构：
[1] Univ Klin Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] IDIBELL, Dept Hematol, Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain
[3] Azienda Osped Santa Maria, SC Oncoematol, Terni, Italy
[4] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Hematol, Pierre Benite, France
[5] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy
[6] Jagiellonian Univ, Dept Hematol, Krakow, Poland
[7] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary
[8] Palacky Univ Olomouc, Olomouc, Czech Republic
[9] Univ Hosp Olomouc, Dept Hematooncol, Olomouc, Czech Republic
[10] Catholic Univ Louvain, CHU UCL Namur, Dept Hematol, Yvoir, Belgium
[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy
[12] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England
[13] MorphoSys AG, Planegg, Germany
[14] Ohio State Univ, Dept Internal Med, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA
[15] LMU, Univ Hosp, Med Klin & Poliklin 3, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P260
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [41] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Kim, W. S.
    Ando, K.
    Niitsu, N.
    Ogura, M.
    Takahashi, N.
    Uike, N.
    Eom, H. Seok
    Chae, Y. S.
    Tobinai, K.
    Terauchi, T.
    Tateishi, U.
    Tatsumi, M.
    Suh, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [42] Polatuzumab vedotin (Pola) plus rituximab (R) plus lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
    Diefenbach, Catherine S. Magid
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Panizo, Carlos
    Perez, Jose Maria Arguinano
    Miall, Fiona
    Bastos-Oreiro, Mariana
    Lopez-Guillermo, Armando
    Banerjee, Lalita
    McMillan, Andrew
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Seymour, Erlene Kuizon
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
    Hess, G.
    Thieblemont, C.
    Clausen, M. R.
    Lugtenburg, P.
    Balari, Sureda A.
    Zinzani, P. L.
    Wu, J.
    Finn, L.
    Vindelov, S. D.
    Fox, C. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
  • [44] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Bell, Jill A.
    Cherepanov, Dasha
    Revicki, Dennis
    Speck, Rebecca M.
    Swett, Laura
    Stumpo, Kate
    Rong, Yuanxin
    Gordon, Leo I.
    QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
  • [45] Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
    Ansell, Stephen M.
    Minnema, Monique C.
    Johnson, Peter
    Timmerman, John M.
    Armand, Philippe
    Shipp, Margaret A.
    Rodig, Scott J.
    Ligon, Azra H.
    Roemer, Margaretha G. M.
    Reddy, Nishitha
    Cohen, Jonathon B.
    Assouline, Sarit
    Poon, Michelle
    Sharma, Manish
    Kato, Kazunobu
    Samakoglu, Selda
    Sumbul, Anne
    Grigg, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (06) : 481 - +
  • [46] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ghosh, Nilanjan
    Munoz, Javier
    Morgan, David S.
    Dang, Nam H.
    Knapp, Mark
    Delioukina, Maria
    Kingsley, Edwin C.
    Anh Tran
    Ping, Jerry
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Ruan, Jia
    BLOOD, 2016, 128 (22)
  • [47] Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Goy, Andre
    Provencio, Mariano
    Nagy, Zsolt
    Robak, Tadeusz
    Maddocks, Kami J.
    Buske, Christian
    Korolkiewicz, Roman
    Winderlich, Mark
    Blum, Kristie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Zhu, Jun
    Song, Yuqin
    Guo, Ye
    Zhou, Keshu
    Li, Wenyu
    Yang, Yu
    Cai, Qingqing
    Wang, Zhao
    Yang, Haiyan
    BLOOD, 2023, 142
  • [49] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Ayyappan, Sabarish
    Kim, Won Seog
    Kim, Tae Min
    Walewski, Jan
    Cho, Seok-Goo
    Jarque, Isidro
    Iskierka-Jazdzewska, Elzbieta
    Poon, Michelle
    Oh, Sung Yong
    Lim, Francesca Lorraine Wei Inng
    Carpio, Cecilia
    Tan, Tran-Der
    Gutierrez, Antonio
    Zhang, Huilai
    Cao, Junning
    Zhang, Mingzhi
    Tessoulin, Benoit
    Li, Jingjin
    Ufkin, Melanie
    Shariff, Saleem
    Chi, Lei
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Prince, H. Miles
    BLOOD, 2023, 142
  • [50] SUBGROUP ANALYSES OF DIFFUSE LARGE B-CELL LYMPHOMA AND INDOLENT LYMPHOMA COHORTS FROM A PHASE IIA STUDY OF SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
    Jurczak, W.
    Zinzani, P. L.
    Gaidano, G.
    Goy, A.
    Provencio, M.
    Nagy, Z.
    Robak, T.
    Maddocks, K.
    Buske, C.
    Ambarkhane, S.
    Winderlich, M.
    Endell, J.
    Blum, K.
    HAEMATOLOGICA, 2016, 101 : 317 - 317
12345